Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

被引：2
|
作者：
Rodriguez, Cesar [1 ]
Weisel, Katja [2 ]
Baz, Rachid C. [3 ]
Polepally, Akshanth R. [4 ]
Ross, Jeremy A. [4 ]
Jin, Ziyi [4 ]
D'Amico, Kristin [4 ]
Bueno, Orlando F. [4 ]
Fleming, Leanne Lash [4 ]
Voorhees, Peter M. [5 ]
机构：
[1] Wake Forest Univ Sch Med, Med Oncol & Hematol, Winston Salem, NC USA
[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] AbbVie Inc, N Chicago, IL USA
[5] Atrium Hlth Wake Forest Baptist, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Plasma Cell Disorders Sect, Charlotte, NC USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157977
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7326 / 7327
页数：2
相关论文
共 50 条
  • [41] Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
    Dinner, Shira N.
    Dunn, Tamara J.
    Medeiros, Bruno C.
    Coutre, Steven E.
    Berube, Caroline
    Gotlib, Jason
    Liedtke, Michaela
    BLOOD, 2012, 120 (21)
  • [42] Anti-Cancer Effects of Clofazimine As a Single Agent and in Combination with Cisplatin in Multiple Myeloma
    Durusu, Ipek
    Husnugil, Hazal Hepsen
    Atas, Heval
    Biber, Aysenur
    Gerekci, Selin
    Gulec, Aliye Ezgi
    Ozen, Can
    BLOOD, 2016, 128 (22)
  • [43] Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma
    Wang, Chunling
    He, Zhengmei
    Shi, Yuye
    Zhang, Lijuan
    Chen, Yue
    Chen, Zhi
    Yu, Liang
    HEMATOLOGY, 2017, 22 (02) : 88 - 92
  • [44] Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma.
    Di Raimondo, F
    Pennisi, A
    Buglio, D
    Fiumara, P
    Palumbo, GA
    Giustolisi, R
    BLOOD, 2003, 102 (11) : 385B - 385B
  • [45] Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
    Chen, Christine
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Sutherland, Heather J.
    White, Darrell
    Venner, Christopher P.
    Kouroukis, Tom
    Bergstrom, Debra
    McCurdy, Arleigh
    Lalancette, Marc
    Bensinger, William
    Lentzsch, Suzanne
    Del Col, Aldo
    Kauffman, Michael
    Shacham, Sharon
    Jeha, Jacqueline
    Picklesimer, Carla
    Saint-Martin, Jean-Richard
    Choe-Juliak, Cassandra
    Bahlis, Nizar J.
    BLOOD, 2016, 128 (22)
  • [46] CM313 Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter, Phase 1 Dose-Escalation and Dose-Expansion Trial
    Zhou, Huixing
    Huang, Zhongxia
    Fang, Baijun
    Jing, Hongmei
    Xia, Zhongjun
    Song, Yuqin
    Cai, Zhen
    An, Gang
    Qin, Ling
    Bao, Li
    Li, Xin
    Liu, Yuzhang
    Wang, Yanrong
    Li, Ling
    Chen, Wenming
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (03) : 531 - 534
  • [47] A phase 1, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM).
    Wang, M
    Talpaz, M
    Jagannath, S
    Chanan-Khan, AA
    Alexanian, R
    Weber, DM
    Gavino, M
    Estrov, Z
    Harris, PJ
    Picker, D
    Schlossman, RL
    Tassone, P
    Anderson, KC
    Munshi, NC
    BLOOD, 2005, 106 (11) : 36A - 37A
  • [48] A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
    Walling, Jackie M.
    Matusow, Bernice
    Nichols, Christine
    Singh, Parmveer
    Inokuchi, Kerry
    Bollag, Gideon
    BLOOD, 2024, 144 : 7022 - 7023
  • [49] A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma
    Shah, Nina D.
    Turtle, Cameron J.
    Cowan, Andrew J.
    Chavez, Julio C.
    Budde, Lihua E.
    Marcondes, Mario Q.
    Lee, Zachary
    Lin, Wei
    Zalevsky, Jonathan
    Tagliaferri, Mary
    Patel, Krina K.
    BLOOD, 2019, 134
  • [50] Results of Study CC-220-MM-001 Dose Expansion of Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients with Relapsed/Relapsed-Refractory Multiple Myeloma (RRMM)
    Knop, S.
    Lonial, S.
    Popat, R.
    Hulin, C.
    Jagannath, S.
    Oriol, A.
    Richardson, P. G.
    Facon, T.
    Weisel, K.
    Larsen, J. T.
    Minnema, M. C.
    Abdallah, A. -O. A.
    Badros, A. Z.
    Stadtmauer, E. A.
    Chen, M.
    Nguyen, T., V
    Amin, A.
    Peluso, T.
    van de Donk, N. W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 247 - 247
12345